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Abstract: The oceans remain a major source of natural compounds with potential in 
pharmacology. In particular, during the last few decades, marine cyanobacteria have been 
in focus as producers of interesting bioactive compounds, especially for the treatment of 
cancer. In this study, the anticancer potential of extracts from twenty eight marine 
cyanobacteria strains, belonging to the underexplored picoplanktonic genera, Cyanobium, 
Synechocystis and Synechococcus, and the filamentous genera, Nodosilinea, Leptolyngbya, 
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Pseudanabaena and Romeria, were assessed in eight human tumor cell lines. First, a crude 
extract was obtained by dichloromethane:methanol extraction, and from it, three fractions 
were separated in a Si column chromatography. The crude extract and fractions were tested 
in eight human cancer cell lines for cell viability/toxicity, accessed with the  
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and lactic 
dehydrogenase release (LDH) assays. Eight point nine percent of the strains revealed strong 
cytotoxicity; 17.8% showed moderate cytotoxicity, and 14.3% assays showed low toxicity. 
The results obtained revealed that the studied genera of marine cyanobacteria are a 
promising source of novel compounds with potential anticancer activity and highlight  
the interest in also exploring the smaller filamentous and picoplanktonic genera  
of cyanobacteria. 
Keywords: marine cyanobacteria; natural products; anticancer potential 
 
1. Introduction 
Exploring the potential bioactivities of organisms is still a remarkable tool for the development of 
new pharmacological products [1]. Despite the progresses in drug synthesis, screening natural 
compounds directly from the producer organism still provides a high percentage of new compounds 
for clinical trials [2]. 
The ocean hosts an unmeasured biological and chemical diversity, which led to an increased 
research effort in natural products. Marine cyanobacteria, in particular, have become a promising 
source of new compounds with interest in pharmacology and biotechnology [3]. Despite their relative 
simplicity, cyanobacteria are spread through the whole range of marine environments, revealing a high 
capacity of adaptation. Concerning the production of bioactive compounds, a single cyanobacterial 
strain is capable of producing an array of secondary metabolites with distinct chemical arrangements 
and interesting bioactivities. As an example, a Lyngbya majuscula strain collected in Grenada was 
found to produce two new halogenated fatty acid amides (grenadamides B and C), two depsipeptides, 
(itralamides A and B) and two lipopeptides (hectochlorin and deacetylhectochlorin) [4]. 
As a result of exploring cyanobacteria for bioactive natural products, many compounds were described, 
and in bioassay-guided fractionation screenings, many revealed antibacterial [5], antimalarial [6] and 
anti-inflammatory [7] activities. However, despite the large array of bioactivities of the compounds, 
researchers have focused on their potential as anticancer drugs. Several compounds isolated from 
marine cyanobacteria demonstrated strong cytotoxicity against human tumor cells [8–10]. Apratoxin D 
(Figure 1), from Lyngbya majuscula and Lyngbya sordida collections, showed an IC50 value of 2.6 nM 
against H-460 human lung cancer cells [9]. Symplostatin 1 (Figure 1), isolated from a Symploca hydnoides 
strain, induces cell death in the MDA-MB-435 breast carcinoma cell line with an IC50 of 0.15 nM and 
in NCI/ADR ovarian carcinoma cells with an IC50 of 0.09 nM [11]. 
The cytotoxicity of cyanobacterial natural compounds in cancer cell lines is induced by different 
mechanisms. Coibamide, a cyclic depsipeptide, isolated from a Panamanian Leptolyngbya sp. strain, 
causes cell cycle arrest in the G1 phase in MDA-MB-435 breast cancer cells [12]. Bouillomides A and 
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B, another two depsipeptides isolated from Lyngbya bouillonii, were found to specifically and strongly 
inhibit serine proteases elastase and trypsin [13]. Other marine cyanobacteria compounds are capable 
of inducing oxidative stress and DNA fragmentation, microfilament disruption, Bcl-2 protein family 
modulation and even alterations in cell membrane dynamics [14–17]. 
Figure 1. Chemical structures of the marine cyanobacteria secondary metabolites, 
apratoxin D and symplostatin 1. 
Symplostatin 1Apratoxin D  
The majority of the described natural compounds produced by marine cyanobacteria were isolated 
from filamentous species that grow in large densities along the shores and, consequently, are easy to 
collect [18]. Among these cyanobacteria, the genus Lyngbya, or Moorea for some strains, as recently 
found [19,20], has been the most prolific. We believe that the higher success of these filamentous 
cyanobacteria is due to a biased research effort. This bias seems to be due to an easier collection of 
biomass from these cyanobacteria in the field. Due to their slower growth in environmental conditions, 
other cyanobacteria groups, such as the picoplanktonic Cyanobium, Synechocystis and Synechococcus 
and the filamentous Nodosilinea, Leptolyngbya, Pseudanabaena and Romeria, have been largely 
overlooked. These cyanobacteria genera constitute a large fraction of the marine cyanobacterial strains 
isolated from the Portuguese coast and maintained in the culture collection of our research institution. 
In the present study, we aimed to evaluate the bioactive potential of strains belonging to these genera, 
by screening their cytotoxicity in human cancer lines. A crude extract from twenty eight cyanobacteria 
strains was obtained by dichloromethane:methanol extraction. This extract was further fractionated 
into three fractions, in Si column chromatography. Fractions A, B and C, were eluted according to  
their polarity with a stepped gradient from 100% hexane, 100% ethyl acetate and 100% methanol.  
Cell toxicity was evaluated on eight cancer cell lines by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide assay (MTT). The stronger positive results from MTT were tested by the lactic 
dehydrogenase release assay (LDH), in order to select the most promising strains for the further 
isolation of bioactive compounds. 
2. Results 
The results obtained with the MTT assay are summarized in Table 1 and Figures 2–4. This initial 
screening led to the identification of strains producing stronger cytotoxic effects on cancer cell lines.  
In Table 1, we present a classification of the cytotoxicity of each cyanobacteria strain globally, on each 
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cell line. For each cell line, the strains were included in different classes: ―strong cytotoxic‖, 
―moderately cytotoxic‖, ―low cytotoxic‖ and ―no cytotoxic‖. These classes were established based on 
the percentiles of the distribution of the standardized average effect on cell viability, which were above 
the 90th percentile when standardized cell viability was less than 10%, between the 70th and  
90th percentile when standardized cell viability was between 30% and 10% and between the 50th and 
70th when standardized cell viability was between 50% and 30%, respectively. The distribution of this 
variable was assumed to be random normal. Standardization was performed with the t statistic. 
Table 1. Summary of cell viability data from the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-di 
phenyl tetrazolium bromide) assays, after exposure to the cyanobacterial crude extract and 
A, B and C fractions. +++ indicates strong toxicity (higher than the 90th percentile of the 
effect on cell viability); ++ indicates moderate toxicity (the 70th–90th percentile of the 
effect on cell viability); + indicates low toxicity (the 50th–70th percentile of the effect on 
cell viability); − indicates no toxicity (less than the 50th percentile of the effect on  
cell viability). LEGE, Laboratory of Ecotoxicology, Genomics and Evolution. 
Strain 
Cancer Cell Lines 
HepG2 RKO MG-63 SK-BR-3 T47D HT-29 SH-SY5Y PC-3 
Nodosilinea nodulosa  LEGE 06152 − − − − − +++ + +++ 
Leptolyngbya cf. halophila LEGE 06102 +++ + ++ − − ++ + ++ 
Leptolyngbya mycoidea LEGE 06108 − − − − ++ − − − 
Leptolyngbya mycoidea LEGE 06118 + + ++ − ++ + ++ − 
Leptolyngbya mycoidea LEGE 06009 − − − − ++ +++ + ++ 
Leptolyngbya fragilis LEGE 07167 ++ ++ +++ ++ +++ + +++ +++ 
Pseudanabaena aff. curta LEGE 07160 − + + − − ++ − ++ 
Pseudanabaena aff. curta LEGE 07169 ++ − +++ + ++ +++ − +++ 
Pseudanabaena aff. persicina LEGE 07163 − − − − − − − − 
Pseudanabaena sp. LEGE 06144 +++ − − +++ + − − − 
Pseudanabaena sp. LEGE 06194 − − − − − − − − 
Cyanobium sp. LEGE 06098 − − ++ + − − ++ − 
Cyanobium sp. LEGE 06134 − − + − − + − − 
Cyanobium sp. LEGE 07175 + − ++ − ++ − − − 
Cyanobium sp. LEGE 07186 − − ++ − ++ ++ − ++ 
Cyanobium sp. LEGE 06113 +++ − + ++ − − ++ − 
Cyanobium sp. LEGE 06137 − ++ − − − − + − 
Cyanobium sp. LEGE 06097 + − − − ++ + − − 
Cyanobium sp. LEGE 06139 − ++ − − + − + − 
Synechococcus nidulans LEGE 07171 + − − +++ − − ++ − 
Synechococcus sp. LEGE 07172 − ++ − − − − ++ − 
Synechococcus sp. LEGE 06005 − − ++ − − − − − 
Synechococcus sp. LEGE 06026 − − − + − + − − 
Synechocystis salina LEGE 06099 +++ − ++ +++ − − + − 
Synechocystis salina LEGE 06155 +++ +++ + ++ + + ++ − 
Synechocystis salina LEGE 07173 + − − − + − ++ − 
Romeria sp. LEGE 06013 − ++ − − − − + − 
Romeria aff. gracilis LEGE 07310 + − + +++ ++ − ++ − 
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Figure 2. Results of all individual experiments of the MTT assay. The percentage of  
cell viability was calculated relative to the control. Dark dots (arrows indicate examples) 
are indicative of strong and moderate cytotoxicity (CR100, 10 and 1: crude extract at 100, 
10 and 1 μg·mL−1; A100, 10 and 1: fraction A at 100, 10 and 1 μg·mL−1; B100, 10 and 1: 
fraction B at 100, 10 and 1 μg·mL−1; C100, 10 and 1: fraction C at 100, 10 and 1 μg·mL−1). 
 
Figure 3. Global toxicity of cyanobacterial strains. The average effect of strains on  
cell viability was calculated with respect to the positive control and standardized with the  
t statistic (n ~ 857). Error bars show the standard error of the estimated difference. 
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Figure 4. Global toxicity of the cyanobacterial crude extract (Cr) and fractions A, B and C.  
The average effect of extract on cell viability was calculated and standardized, as in Figure 3 
for each extract (n ~ 6,003). Error bars show the standard error of the estimated difference. 
 
Within this distribution, the effect of 8.9% of the strains was above the 90th percentile, which was 
considered a strong cytotoxic effect; 17.8% was between the 70th and 90th percentiles, which was 
considered as moderate cytotoxicity, and 14.3% appeared between the 50th and 70th percentiles, 
which was considered a low toxicity effect. The remaining 59% of strains were below the 50th 
percentile, considered as having no cytotoxic effect. However, the majority of the tested cyanobacterial 
strains were capable of inducing cytotoxicity in at least one of the cell lines (Table 1). In Figure 3 are 
shown the global results of the effect on cell viability for each cyanobacterial strain, extract and extract 
concentration, pooling all the cancer cell lines, times of exposure and individual replicates. In almost 
all strains, dark spots are present (the arrows indicate example) indicative of strong and moderate 
cytotoxic effects. Strain Leptolyngbya fragilis LEGE (Laboratory of Ecotoxicology, Genomics and 
Evolution) 07167 and Synechocystis salina LEGE 06155 (Figure 5) were the most cytotoxic strains 
(Figures 2 and 3) with above the 90th percentile of the standardized effect on cancer cell viability, 
classified as a strong effect. Strains Pseudanabaena aff. LEGE 07163 and Pseudanabaena sp. LEGE 
06194 were not found to induce cytotoxicity in any of the assays, representing only 7.2% of the 
cyanobacteria strains under study. Figure 4 shows that the crude extract was the most cytotoxic to the 
cancer cell lines, followed by fraction B. Fraction C was the one with the least bioactivity. 
Figure 5. Micrographs of the cyanobacteria strains, Leptolyngbya fragilis LEGE 07167 (a) 
and Synechocystis salina LEGE 06155 (b). 
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The assays where a strong cytotoxic effect was registered were additionally subjected to the  
LDH assay. As a comparison between MTT and LDH assays, Table 2 shows the fractions with higher 
cytotoxicity on each cell line for each of the strains tested. Extract B from the Synechocystis salina 
LEGE 06155 was the fraction with higher activity in both assays in HepG2 and RKO (Figure 6). 
Fraction A of the Synechocystis salina LEGE 06099 was also the most active fraction when tested in 
the HepG2 cell line. Furthermore, fraction A of the Leptolyngbya cf. halophila LEGE 06102 was the 
most active when tested with LDH and MTT assays. 
Table 2. Summary of the results obtained with the two cytotoxic assays. The most active 
fractions are indicated and the concordant results highlighted in grey. The strains with no 
active fraction are marked with a hyphen. 
Cell line Strain MTT LDH 
HepG2 
LEGE 06155 B B 
LEGE 06099 A A 
LEGE 06102 A A 
LEGE 06113 B A 
LEGE 06144 Crude - 
HT-29 
LEGE 07169 C A 
LEGE 06009 Crude - 
LEGE 06152 B B 
MG-63 
LEGE 07169 B - 
LEGE 07167 Crude, A, B, C - 
PC-3 
LEGE 07169 A - 
LEGE 06009 A A 
LEGE 06152 Crude, A, B, C - 
RKO LEGE 06155 B B 
SH-SY5Y LEGE 07167 B - 
T47D LEGE 07167 B Crude 
Figure 6. Cytotoxicity/cell viability induced by crude extract (Cr) and fractions (Fr.) of the 
Synechocystis salina LEGE 06155 on RKO and HepG2 cell lines, measured with MTT and 
LDH (lactic dehydrogenase release) assays. (a) RKO cell line, MTT assay; (b) RKO cell 
line, LDH assay; (c) HepG2 cell line, MTT assay; and (d) HepG2 cell line, LDH assay.  
* p < 0.001. 
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However, the activity shown by each fraction in the MTT assay was not always confirmed by the 
LDH assay. Fraction B of Nodosilinea nodulosa LEGE 06152 was the most active in both assays when 
tested in the HT-29 cell line. However, in PC-3, all the extracts showed activity when tested with the 
MTT assay, whereas this activity was not seen with the LDH. A similar profile was shown by 
Leptolyngbya mycoidea LEGE 06009, for which, when tested with both toxicological assays in PC-3, 
fraction A was the most active. In the HT-29 cell line, however, the crude extract showed the highest 
activity, but this activity was not detected with the LDH assay. 
The strain, Pseudanabaena aff. curta LEGE 07169, appeared with a strong activity in several of  
the cell lines from this study: HT-29, MG63 and PC-3. However, the most active fraction detected by 
the MTT and LDH assays was not the same. Fractions A, B and C appear to induce cytotoxic effects 
with the MTT assay. When the LDH assay was applied, fraction A showed cytotoxicity in the HT-29 
cell line, but for MG63 and PC-3 cell lines, the cytotoxic effect was not confirmed. 
Leptolyngbya fragilis LEGE 07167, one of the two strains with a stronger activity, when tested with 
the MTT assay in SH-SY5Y and in T47D cell lines pointed out fraction B as the most active. In the 
MG63 cell line, all the fractions appeared to be strongly active. However, in the LDH assay, the crude 
extract appeared as the most active in the T47D cell line. In SH-SY5Y and MG63, no activity  
was detected. 
3. Discussion 
Picoplanktonic and filamentous marine cyanobacteria of genera Nodosilinea, Cyanobium, 
Synechocystis, Synechococcus, Leptolyngbya, Pseudanabaena and Romeria have been rarely studied 
with respect to their potential as producers of interesting bioactive compounds. In this study, we found 
that strains from those genera were able to induce cytotoxic effects in human cancer cell lines. Since 
these strains were not found to grow naturally in large densities, massive growth under laboratory 
conditions was necessary for biomass production. 
Bioassays-guided fractionation is a methodology that has been successfully used in the isolation and 
identification of marine natural compounds, as it allows the quick recognition of the active fractions 
that may contain interesting compounds [21–23]. The search for new anticancer drugs has been 
currently associated with this approach [8,24,25]. In this work, cyanobacteria crude extract and 
fractions obtained by chromatography of twenty eight strains were tested in eight cancer cell lines, 
which were selected as being representative of several human tumors. By increasing the range of cell 
lines, we were able to increase the probability of obtaining cytotoxic effects. 
Two of the most common cytotoxicity assays were applied in order to increase the consistency  
of results and to identify more precisely the potentially interesting cyanobacteria strains. When the 
results of both assays were compared, six cyanobacteria strains were shown to be the most interesting 
for the isolation of bioactive compounds: Synechocystis salina LEGE 06155 and LEGE 06099, 
Leptolyngbya cf. halophila LEGE 06102, Leptolyngbya mycoidea LEGE 06009, Leptolyngbya fragilis 
LEGE 07167 and Nodosilinea nodulosa LEGE 06152. The results from both assays did not match 
perfectly. This was already observed in other studies in which the MTT and LDH assays were tested 
together [26–28]. The MTT assay is clearly the most sensitive assay, since the rate of cytotoxicity 
caused by the cyanobacteria extracts observed with this assay was generally higher than that observed 
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with the LDH assay. This can be explained by the fact that each assay is based on different  
cellular events. The lactate dehydrogenase assay is based on the release of the enzyme into the culture 
medium after cell membrane damage. Thereby, the assay is satisfactory when agents that induce cell 
membrane damage are involved in the mechanism. Certain cytotoxic metabolites could cause cell 
alterations only in intracellular activities or organelles and do not affect the membrane; in those cases, 
the toxicity would not be detected [29]. The MTT assay is based on the enzymatic reduction of the  
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) into a blue colored formazan in 
the mitochondria. As with the LDH, some cytotoxic metabolites could be missed, since the metabolite 
could affect some cell organelles without interfering with the mitochondrial functions [29]. In addition, 
cytotoxic events can occur with different timing, initially affecting the mitochondria and, later,  
the membrane. 
Still, considering both MTT and LDH results and using a bioassay-guided fractionation, HepG2  
and RKO cell lines could be used to isolate a possible compound(s) present in fraction B of 
Synechocystis salina LEGE 06155, as this was one of the two strains inducing stronger toxicity. 
Fractions A of Leptolyngbya cf. halophila LEGE 06102 and Synechocystis salina LEGE 06099 also 
have interest for the isolation of an anticancer compound using the HepG2 cell line. Fraction B of 
Nodosilinea nodulosa LEGE 06152 and fraction A of Leptolyngbya mycoidea LEGE 06009 can also 
be explored using HT-29 and PC-3, respectively. 
The strains, Leptolyngbya fragilis LEGE 07167 and Synechocystis salina LEGE 06155, were shown 
to be the most bioactive in the tested cancer cell lines. Several bioactive compounds with anticancer 
properties were already isolated from Leptolyngbya genera. Coibamide A, isolated from a Leptolyngbya 
strain collected in Coiba National Park (Coiba Island, Panama), demonstrated anticancer activity 
against lung cancer NCI-H460, breast cancer MDA-MB-231, melanoma LOX IMVI, leukemia HL-60 
and astrocytoma SNB75 [12]. Dolastatin 12, isolated from a strain collected in the Red Sea, was 
cytotoxic to mouse neuro-2a blastoma cells [24]. From Synechocystis genera, several fatty acids, volatile 
compounds and pigments were already isolated [30], but to the best of our knowledge, any bioactive 
anticancer compound was already identified. 
Considering the MTT screening assay, all but two of the selected cyanobacteria strains revealed 
bioactivity. However, in many cases, the cytotoxic effect was evident only for the 100 μg·mL−1 
concentration. This concentration was already demonstrated to be the most effective in a screening 
performed by Leão and co-workers using likewise marine cyanobacteria extracts and testing them in 
several ecologically-relevant bioassays [31]. Previous similar cytotoxicity screenings with terrestrial 
and freshwater cyanobacteria strains also showed positive results in a large portion of extracts, 
although not so strong as in this study [32–34]. 
Crude extract was globally the most bioactive. This finding can be explained by the presence of  
a cocktail of bioactive compounds, since all the compounds produced by the cyanobacteria and then 
fractionated into fractions A, B and C would be included in this extract. Fraction B is the second most 
active. It contains the compounds with intermediate polarity, since it was eluted from the column with 
the solvents with intermediate polarity (a higher percentage of ethyl acetate). This fraction usually 
contains several classes of peptides and depsipeptides. In fact, many compounds belonging to these 
chemical classes were already described and isolated from marine cyanobacteria and demonstrated to 
have anticancer potential [7,10,35]. In some cases, like the strain, Pseudanabaena aff. curta  
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LEGE 07169, more than just one fraction was shown to be bioactive. This could be explained by  
the presence of the same compound in adjacent fractions, since the fractions are removed gradually 
from the column, and/or by the presence of more than one compound with anticancer properties. 
Some strains of the genera included in this study, namely Cyanobium, Synechocystis, 
Synechococcus and Leptolyngbya, were already identified as a potential source of bioactive 
compounds, based on screenings with mammals [36], invertebrates [37,38] virus, bacteria and some 
cell lines [39,40], although only compounds from Leptolyngbya were yet isolated [12,24]. The results 
obtained in the present study allow us to confirm the interest of this picoplanktonic and filamentous 
genera as a source of anticancer compounds. 
4. Experimental Section 
4.1. Cyanobacteria Strains and Culture 
Twenty eight marine cyanobacterial strains belonging to the coccoid genera, Cyanobium, 
Synechocystis and Synechococcus, and the filamentous genera, Nodosilinea, Leptolyngbya, 
Pseudanabaena and Romeria, were employed in this study (Table 3). Strains were isolated from  
the Portuguese coast (Figure 7) and are maintained in the LEGE (Laboratory of Ecotoxicology, 
Genomics and Evolution, (Porto, Portugal) culture collection. Large-scale cultures of these strains 
were set for biomass production. Strains were grown in Z8 medium [41], supplemented with 20 g·L
−1
 
NaCl, or in MN medium [42] (Table 3). Cultures were maintained at 25 °C, with a light intensity of 
10 μmol photons m−2·s−1 and with a light/dark cycle of 14:10 h. At the exponential growth phase, cells 
were harvested by centrifugation, frozen at −20 °C and freeze-dried. The lyophilized biomass was 
stored at −20 °C. 
Table 3. Marine cyanobacteria strains included in this study, origin, accession number and 
culture medium. 
Taxon Code Sampling Location Accession Number Reference  Medium 
Nodosilinea nodulosa LEGE 06152 Lavadores (4) HQ832915 [31] Z8 
Leptolyngbya cf. halophila LEGE 06102 S. Bartolomeu do Mar (2) HQ832906 [43] Z8 
Leptolyngbya mycoidea LEGE 06108 Luz (11) HQ832942 [43] Z8 
Leptolyngbya mycoidea LEGE 06118 Luz (11) HQ832943 [43] Z8 
Leptolyngbya mycoidea LEGE 06009 Foz do Arelho (7) JF708121 [43] Z8 
Leptolyngbya fragilis LEGE 07167 Lavadores (4) HQ832917 [43] MN 
Pseudanabaena aff. curta LEGE 07160 Olhos d’Água (12) HQ832948 [43] MN 
Pseudanabaena aff. curta LEGE 07169 Aguda (5) HQ832923 [43] MN 
Pseudanabaena aff. persicina LEGE 07163 Moledo (1) HQ832900 [43] MN 
Pseudanabaena sp. LEGE 06144 Burgau (10) HQ832937 [43] MN 
Pseudanabaena sp. LEGE 06194 Luz (11) - - MN 
Cyanobium sp. LEGE 06098 Martinhal (9) KC469572 [44] Z8 
Cyanobium sp. LEGE 06134 Moledo (1) KC469573 [44] Z8 
Cyanobium sp. LEGE 07175 Martinhal (9) KC469575 [44] Z8 
Cyanobium sp. LEGE 07186 Martinhal (9) KC469576 [44] Z8 
Cyanobium sp. LEGE 06113 Aguda (5) KC469577 [45] Z8 
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Table 3. Cont. 
Cyanobium sp. LEGE 06137 Lavadores (4) HQ832914 [43] Z8 
Cyanobium sp. LEGE 06097 Martinhal (9) HQ832928 [43] Z8 
Cyanobium sp. LEGE 06139 Aguda (5) KC469574 [44] Z8 
Synechococcus nidulans LEGE 07171 Burgau (10) HQ832939 [43] Z8 
Synechococcus sp. LEGE 07172 Olhos d’Água (12) HQ832950 [43] Z8 
Synechococcus sp. LEGE 06005 São Pedro de Moel (6) HM124558 [37] Z8 
Synechococcus sp. LEGE 06026 Empa (8) - - Z8 
Synechocystis salina LEGE 06099 Moledo (1) HQ832895 [43] Z8 
Synechocystis salina LEGE 06155 S. Bartolomeu do Mar (2) HQ832911 [43] Z8 
Synechocystis salina LEGE 07173 Olhos d’Água (12) HQ832951 [43] Z8 
Romeria sp. LEGE 06013 Foz do Arelho (7) HQ832927 [43] Z8 
Romeria aff. gracilis LEGE 07310 Minho estuary (3) HM217057 [46] Z8 
Figure 7. Location of the rocky beaches from where cyanobacteria strains were isolated. 
The numbers correspond to rocky beaches, referring to the sampling location in Table 3. 
 
4.2. Extract Preparation 
A crude organic extract was obtained by repeated extraction of approximately 1 g (dry weigh) of 
cyanobacterial biomass. Extraction was performed with CH2Cl2:MeOH (2:1) at room temperature and 
40 °C. This crude extract was fractioned by vacuum liquid chromatography, by injection in  
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SiOH normal phase SPE cartridge (Strata SI-1, Phenomenex), using a gradient elution from  
hexane-EtOAc-MeOH, yielding three fractions, hereafter A, B and C, respectively. The crude extract 
and fractions were solubilized in dimethyl sulfoxide (DMSO). 
4.3. Cell Lines 
Human colon adenocarcinoma (HT-29), neuroblastoma (SH-SY5Y) and breast carcinoma cell lines 
T47D were purchased from Sigma-Aldrich. PC-3 prostate adenocarcinoma, SK-BR-3 breast 
adenocarcinoma, RKO colon carcinoma, hepatocellular carcinoma HepG2 and MG-63 osteosarcoma 
cell lines were obtained from the American Type Culture Collection (ATCC). Cell lines were 
cultivated in modified Eagle medium (DMEM Glutamax), except PC-3, which was grown in minimal 
essential medium (α-MEM), and SH-SY5Y, grown in HAM F12 Medium. DMEM Glutamax and  
α-MEM mediums were supplemented with 10% fetal bovine serum (FBS), 2.5 μg·mL−1 fungizone, 
penicillin-streptomycin (100 IU·mL
−1
 and 100 μg·mL−1, respectively). HAM F12 medium was 
supplemented with 2 mM glutamine, 1% non-essential amino acids and 15% FBS. Cells were 
incubated in a humidified atmosphere with 5% of CO2, at 37 °C. Culture medium was renewed every 
two days. At 80%–90% cell confluence, adherent cells were enzymatically released with a solution of 
0.05% trypsin in 0.25% EDTA. 
4.4. Cytotoxicity Assays 
4.4.1. MTT Assay 
Cellular viability was evaluated by the reduction of the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT, Sigma-Aldrich, St. Louis, MO, USA). All cell lines were seeded in  
96-well culture plates at 10
4
 cells·cm
−2
, except SH-SY5Y, which were seeded at 3.1 × 10
4
 cells·cm
−2
. 
Cells adhesion was allowed during 24 h. Then, cells were incubated in new medium with the crude 
extract and fractions at 100, 10 and 1 μg mL−1 and 1% DMSO as the negative control during 24, 48 
and 72 h. After treatments, cells were incubated 4 h, at 37 °C, with 0.05 mg mL
−1
 MTT. The purple 
colored formazan salts formed were dissolved in DMSO, and the absorbance was read at 550 nm in  
a GEN5TM-Multi-detection Microplate Reader (Biotek, Bad Friedrichshall, Germany). All assays 
were run in triplicate and averaged. Cytotoxicity was expressed as a percentage of cell viability 
considering 100% viability in the negative control (cells treated with 1% DMSO). 
4.4.2. LDH Release Assay 
The LDH release was assessed using the In Vitro Toxicology Assay Kit, Lactic  
Dehydrogenase-based (TOX7, Sigma-Aldrich), according to the manufacturer’s instructions. Cell lines 
were seeded in 96-well culture plates at 3.1 × 10
4
 cells cm
−2
. After 24 h of adhesion, cells were exposed 
to new medium with the crude extract and fractions at 100 μg mL−1 for 24, 48 and 72 h. A positive 
control, leading to 100% cytotoxicity by lysing the cells completely, was included in the assay. 
The LDH values were measured at 490 nm, with 690 nm as the reference in a  
GEN5™-Multi-detection Microplate Reader (Biotek). All the assays were run in triplicate and 
averaged. The amount of LDH leakage to the medium was calculated according to the formula: 
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LDH leakage (%) = LDH medium/total LDH × 100 (1) 
4.5. Statistical Analysis 
Our main approach to analyze data was using general linear models. A single analysis was 
performed for each cyanobacterial strain. The percentage of viability was used as the dependent 
variable. The extract, concentration and time of incubation were used as fixed factors. If any of these 
factors was not significant, it was removed from the model. 
Normality was tested in the model residuals with the Shapiro–Wilk test. In those cases where 
residual distribution was not normal, the data were normalized. In order to do so, preferably, the data 
were transformed using the Box-Cox function. If this first approach did not work, outliers with  
a Cook distance >0.5 were removed. After outlier removal, data might be transformed again with the 
Box–Cox function, if needed. The number of outliers removed, if any, never exceeded 1% of the  
total data. If this approach combining outlier removal and data transformation failed, a generalized 
linear model was employed, with the gamma distribution as the error distribution function. In these 
cases, the goodness of fit to gamma distribution was tested in the dependent variable with a χ2 test. The 
vast majority of the analyses were, however, general linear models. Post hoc pairwise comparisons 
among factor levels were performed with the Tukey test. Homogeneous subsets of treatment levels 
were obtained based on the significance levels of the Tukey pairwise comparisons. Those levels that 
did not differ significantly among them were classified into the same subset. 
The software employed was R version 2.15.2 (R Foundation for Statistical Computing, Vienna, 
Austria) with functions from the base, stats, car, multcomp and nlme packages. 
5. Conclusions 
Picoplanktonic marine cyanobacteria of genera Cyanobium, Synechocystis, Synechococcus and 
filamentous forms of the genera, Nodosilinea, Leptolyngbya, Pseudanabaena and Romeria, isolated 
from the Portuguese coast, revealed high potential as a source of anticancer compounds.  
By performing an intensive screening applying the two most common cytotoxicity assays, MTT and 
LDH, we were able to select six cyanobacteria strains, from an initial pool of twenty-eight,  
as interesting for the isolation of compounds with potential anticancer activity. The identification of 
new sources of natural products is an important step in drug discovery. In this sense, the results from 
this screening highlight the potential of these marine cyanobacteria genera as a source of interesting 
bioactive compounds. 
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